KS update. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


KS update. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Notes Undergr. 1995 Winter;(no 29):4. Unique Identifier : AIDSLINE AIDS/95700303

Abstract: The Food and Drug Administration (FDA) has recently granted accelerated approval to Liposome Technology, Inc., to market DOX-SL for people with AIDS with refractory Kaposi's sarcoma (KS). DOX-SL, an intravenous drug, is a new form of a regular cancer chemotherapy called doxorubicin, and has dosing schedules similar to standard chemotherapy. The drug, encapsulated in lipid membranes (liposomes), will enable doxorubicin to be delivered directly in a higher concentration to KS lesions, with fewer systemic side effects. The drug will likely be used in combination with standard chemotherapy. Side effects include: hair loss, nausea, and neutropenia. This is the first time the FDA has ever approved a drug for KS.
Keywords: Doxorubicin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE Drug Approval Drug Carriers Human Infusions, Intravenous Liposomes Sarcoma, Kaposi's/*DRUG THERAPY NEWSLETTER ARTICLEKWDdoxorubicin/administration&dosage/adverseeffects/KWDtherapeuticusedrugapprovaldrugcarriershumaninfusions,intravenousliposomessarcoma,kaposi's/KWDdrugtherapynewsletterarticle
950930
M9591267

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .